Acurx Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David Luci
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 259 Liberty Avenue Staten Island NY United States of America 10305
- IPO Date
- Jun 25, 2021
- CIK
- 0001736243
- Website
- acurxpharma.com
- Similar Companies
- Business
- Acurx Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the development of novel anti-infective therapeutics primarily targeting unmet medical needs in infectious diseases. The company's main products and services include the development and commercialization of antibiotic candidates designed to treat serious bacterial infections, with a focus on difficult-to-treat multidrug-resistant pathogens. Its core pipeline features lead compound ACX-362E, an oral therapeutic targeting Clostridioides difficile infections, as well as other antibiotic candidates engineered to address resistant bacterial strains. Acurx operates primarily in the United States, with its research and development headquarters located in New Jersey. Founded in 2017 and headquartered in Bridgewater, New Jersey, Acurx Pharmaceuticals has positioned itself within the pharmaceutical industry’s anti-infective segment, targeting healthcare providers, hospitals, and patients suffering from infectious diseases requiring innovative antibiotic treatments. The company is known for integrating advanced drug discovery and development technologies to accelerate the progression of new antibiotics from preclinical to clinical stages. Recent major company developments include advancing its lead product candidate ACX-362E through clinical trials with positive data supporting its potential efficacy and safety. Acurx also entered into strategic collaborations and licensing agreements to expand its pipeline and enhance its funding and operational capabilities. The company has announced new funding rounds to finance clinical development activities and broaden its antibiotic portfolio, emphasizing its commitment to addressing antibiotic resistance—a critical public health challenge. There have been no recent name changes or reorganizations reported within the last two years. These activities underscore Acurx’s strategic focus on innovative antibiotic development and expansion in the biotechnology pharmaceutical landscape.
Company News
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
Axos Aims to Expand AI-Powered Financial Services With Arc Acquisition
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?